Incannex -IHL-675A Phase 1 clinical trial to assess safety and pharmacokinetics as a potential anti-inflammatory drug candidate
IHL-675A is a cannabinoid combination drug n animal models of: comprising hydroxychloroquine sulphate (‘HCQ’) and cannabidiol (‘CBD’). HCQ is a… Read more